RxDoctor Payments Data

Jenny West

Primary Care · Pensacola, FLNPI 1174842009

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $60,487 of the $80,448 with a category attached, or 75.2%. Novo Nordisk accounts for 62.9% of it on its own, with 41 other manufacturers making up the rest. 2025 is the largest year on record at $37,721, more than ten times the $1,096 reported in 2021. Among primary care clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$80,448in general payments, 2019–2025

Across 600 payments — averaging $134.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$51K
  • Lilly USA, LLC$24K
  • Pfizer$965
  • AbbVie$783
  • Amgen$524
  • Bayer$347
  • plus $3K from 36 others

What the payments were for

  • Speaking & faculty fees$60,48775%
  • Travel & lodging$9,77212%
  • Food & beverage$10,05613%
  • Education$1320%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$80,448 in reported general payments places this provider in the 95th percentile of 725 primary care providers in Florida.

See all primary care providers in Florida

Medicare billing

Part B allowed, 2024
$95,543
Medicare patients
169
Services billed
2,106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide111$143,458
OzempicSemaglutide50$63,076
Repatha SureclickEvolocumab31$30,015
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$21,973
KerendiaFinerenone12$18,131
WegovySemaglutide12$16,250
TrulicityDulaglutide17$15,582
EliquisApixaban19$12,282
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$12,134
Tresiba Flextouch U-100Insulin Degludec14$4,386
Pregabalin50$2,758
Bupropion XlBupropion Hcl63$1,905
Rosuvastatin Calcium138$1,614
Duloxetine Hcl47$1,262
Amlodipine Besylate111$1,259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$24,357$159,040128 claims
Novo NordiskOzempic, Wegovy$50,568$79,32562 claims
GSKTrelegy Ellipta$242$21,97328 claims
BayerKerendia$347$18,13112 claims
PfizerEliquis$965$12,28219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 725 primary care providers in Florida.

Other primary care in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →